First-In-Class Inhibitors Targeting the Interaction between Bacterial RNA Polymerase and Sigma Initiation Factor...

Area of Science:

• Microbiology
• Drug Discovery
• Molecular Biology

Background:

• Multi-drug resistant pathogens pose a significant threat to public health, necessitating novel antimicrobial agents.
• The bacterial RNA polymerase (RNAP)-sigma factor interaction is crucial for transcription and bacterial survival, representing a potential antimicrobial target.
• Previous in silico screening identified a hit compound (C3) targeting this interaction.

Purpose of the Study:

• To experimentally evaluate the antimicrobial activity of compound C3 and its derivatives against pathogens, particularly Streptococcus pneumoniae.
• To assess the potential of these compounds as novel antimicrobial agents targeting RNAP.
• To investigate the effect of the lead compound on bacterial toxin production.

Main Methods:

• Rational design and synthesis of C3 derivatives.
• In vitro antimicrobial susceptibility testing against Streptococcus pneumoniae and other pathogens.
• Assessment of toxin production inhibition in S. pneumoniae.

Main Results:

• Compound C3-005 demonstrated significantly enhanced antimicrobial activity against S. pneumoniae compared to the parent compound C3.
• C3-005 exhibited superior attenuation of S. pneumoniae toxin production compared to existing antibiotic classes.
• The study validated a new antimicrobial agent targeting a previously underexplored mechanism.

Conclusions:

• Compound C3-005 represents a promising lead for the development of novel antibiotics against multi-drug resistant bacteria.
• Targeting the RNAP-sigma factor interaction is a viable strategy for antimicrobial drug discovery.
• Further development of C3-005 and related compounds could provide new therapeutic options for challenging infections.